Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
科研成果: 期刊稿件 › 文章 › 同行评审
136
引用
(Scopus)